Clinical Trial: Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angl

Brief Summary: The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).

Detailed Summary:
Sponsor: Alcon Research

Current Primary Outcome: Mean Intraocular Pressure (IOP) [ Time Frame: 4PM at Week 12 Visit ]

Original Primary Outcome: IOP, IOP change from baseline, and percent change from baseline. [ Time Frame: 9Am and 4Pm at Eligibility Visit and Week 12 Visit,9Am at Week 4 Visit,4Pm at Week 8 Visit ]

Current Secondary Outcome: Number of Patients With Peripheral Anterior Synechiae (PAS) [ Time Frame: Week 12 Visit ]

Original Secondary Outcome: Peripheral anterior synechiae (PAS) [ Time Frame: Eligibility Visit, Week 12 Visit ]

Information By: Alcon Research

Dates:
Date Received: September 24, 2008
Date Started: February 2007
Date Completion:
Last Updated: March 12, 2010
Last Verified: March 2010